Mexico jurisdiction report: Taking care of the pharma sector

This investigation (file number IO-001-2017)  had previously commenced ex officio on June 27, 2017, as a result of evidence suggesting an unlawful transaction among companies and that monopolistic practices, in the form of collusion among companies, price fixing and manipulation, and exchange of information that affects competition, are occurring in several segments of the Mexican private drug market.